Advanced NanoTherapies, Inc. (ANT), a clinical-stage medical technology firm, has successfully closed an oversubscribed Series B financing round, securing over $31 million. The funding, co-led by S3 Ventures and an undisclosed strategic investor, is earmarked to advance the company's novel dual-drug coated balloon platform through pivotal U.S. clinical and regulatory milestones. This capital infusion will support ANT's mission to improve outcomes for patients suffering from coronary and peripheral artery disease.
A New Approach to Vascular Intervention
ANT is pioneering a new paradigm in vascular treatment with its SirPlux Duo drug-coated balloon (DCB), which has received FDA breakthrough designation. The platform utilizes functionalized nanoparticles to deliver two synergistic drugs, paclitaxel and sirolimus, directly to the treatment site. This dual-drug approach is designed to offer superior therapeutic effects and a more predictable vascular response compared to first-generation DCBs that use a single crystalline drug.
Company leadership believes this financing arrives at a critical juncture as the limitations of existing single-drug DCBs become more apparent in the U.S. market. According to CEO Marwan Berrada-Sounni, ANT is uniquely positioned to advance the field with its differentiated nanoparticle technology. This innovative method for local vascular therapy aims to address the long-standing challenges of restenosis, or the re-narrowing of arteries after intervention.
Clinical Validation and Expert Endorsement
The technology, exclusively licensed from Cleveland Clinic, is supported by growing clinical evidence. A first-in-human study involving 28 patients across three countries showed no new treatment failures after a two-year follow-up. An additional 30-patient study is currently underway in Spain, providing further data to support the company's U.S. pivotal trial execution and regulatory submissions.
Medical experts have highlighted the platform's potential to significantly improve patient care. Dr. Rishi Puri of Cleveland Clinic noted the novel platform's ability to deliver two drugs simultaneously, enabling sustained local drug retention at lower doses. Dr. Azeem Latib of Montefiore Einstein described the technology as a "leapfrogging moment" in vascular intervention, offering outcomes comparable to drug-eluting stents without leaving a permanent implant behind.
Strategic Investment and Future Roadmap
The successful financing round, which also included participation from the T45 Fund and other investors, validates the company's progress. Brian R. Smith, Managing Director at S3 Ventures, stated that the investment confirms the strength of ANT's platform and its momentum across scientific, clinical, and regulatory fronts. He emphasized that the company is well-positioned to move toward pivotal execution and bring a differentiated therapy to patients.
With the new capital, ANT plans to scale up its manufacturing capabilities to meet FDA Investigational Device Exemption (IDE) requirements. The company will advance IDE submissions for two coronary indications, in-stent restenosis and small-vessel de novo lesions. Furthermore, ANT will pursue an IDE submission for a U.S. early feasibility study for below-the-knee (BTK) peripheral applications, marking a significant expansion of its clinical program.
This substantial Series B funding round propels Advanced NanoTherapies into its next critical phase of development, providing the resources to navigate the U.S. regulatory landscape. The investment not only validates the company's innovative dual-drug nanoparticle platform but also accelerates its path toward pivotal clinical trials. By addressing the core limitations of current treatments, ANT's technology holds the promise of establishing a new standard of care for vascular disease.